Physiological and Sensory Responses to Prolonged Fasting in Humans (PRO-FAST)

July 26, 2023 updated by: James Betts, University of Bath
This study aims to establish the metabolic/molecular response in both adipose tissue and skeletal muscle as well as sensory experiences (pain, fatigue, drive) to prolonged fasting of 3 days duration. Participants will undergo sequential meal assessment before and after a 3 day fast with measures taken throughout each fasting day.

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Detailed Description

This study will employ a single-arm, non-randomised design in which participants will act as their own control prior to undergoing 3 days of fasting. The control phase includes 3 days of habitual energy balance assessment before coming into the laboratory for baseline meal testing with blood, muscle, and adipose samples as well as anthropometric assessment.

Participants will then be provided with a standardised lunch to be consumed around midday and a standardised dinner to be consumed at 2000 h.

Participants will then be asked to refrain from caloric intake for 3 days until they return to the laboratory for follow up measures.

Participants will be provided with monitoring equipment throughout the 3 days of fasting and will be asked to provide a blood sample at 0800 h each day alongside self recording of blood pressure, weight, and urinary ketones each day. On the middle day (day 2) participants will also be asked to come into the lab to provide a blood sample at 2000 h.

The follow up visit will be identical to that performed before the fast, including meal testing, blood, muscle, and adipose samples.

Study Type

Interventional

Enrollment (Estimated)

7

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Somerset
      • Bath, Somerset, United Kingdom, BA2 7AY
        • University of Bath

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • • Body mass index 20.0-29.9 kg∙m-2

    • Age 18-45 years
    • Willing to abstain from food intake for just over 3 days (~82 hours)
    • Able and willing to provide informed consent and safely comply with study procedures
    • Females to maintain record of regular menstrual cycle phase or contraceptive use
    • No anticipated changes in lifestyle during the study (e.g. holidays or exercise programmes)

Exclusion Criteria:

  • • Any reported condition or behaviour deemed either to pose undue personal risk to the participant or introduce bias

    • Any diagnosed metabolic disease (e.g. type 1 or type 2 diabetes)
    • Any reported use of substances which may pose undue personal risk to the participants or introduce bias into the experiment
    • Pregnancy
    • Breastfeeding
    • Lifestyle not conforming to standard sleep-wake cycle (e.g. shift worker)
    • History of eating disorders (e.g. anorexia)
    • Any reported recent (<6 months) change in body mass (± 3%)
    • Uncontrolled hyperthyroidism
    • Advanced cerebrovascular insufficiency or dementia
    • Advanced liver or kidney insufficiency
    • History of migraine and or headache
    • Psychotic disorders
    • Unstable or severe coronary artery disease
    • Retinal detachment
    • Duodenal or stomach ulcer
    • Cancer and malignant disease
    • Regular use of Non-steroidal anti-inflammatory drugs (NSAIDs)
    • Use of Systemic corticoids
    • Use of Antihypertensives (especially beta-blockers and diuretics)
    • Use of Antidiabetics
    • Use of Anti-coagulants
    • Use of Psychotropics (especially neuroleptics and lithium)
    • Use of Anticonvulsants.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Prolonged Fasting
All participants are asked to act as their own control prior to being asked to undergo 3 days of fasting.
Participants are asked to refrain from caloric intake for 3 days following a period of habitual lifestyle assessment and metabolic assessment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in postprandial insulin responses
Time Frame: 3 days
Change in postprandial insulin (mmol/L) response to a standardised meal before and after 3 days of fasting.
3 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in circulating glycerol and non-esterified fatty acids
Time Frame: 1 day, 2 days, 3 days
Change in indices of lipolysis from adipose tissue in response to prolonged fasting (Glycerol mmol/L; NEFA mmol/L)
1 day, 2 days, 3 days
Change in Autophagy
Time Frame: 3 days
Change in autophagic flux in response to prolonged fasting, assessed in skeletal muscle and circulating neutrophils.
3 days
Change in plasma lactate
Time Frame: 1 day, 2 days, 3 days
Change in plasma lactate in response to prolonged fasting (indices of Cori cycle)
1 day, 2 days, 3 days
Change in plasma pyruvate
Time Frame: 1 day, 2 days, 3 days
Change in plasma pyruvate in response to prolonged fasting (indices of Cori cycle)
1 day, 2 days, 3 days
Change in ketosis.
Time Frame: 1 day, 2 days, 3 days.
Change in urinary (acetoacetate) ketones in response to prolonged fasting.
1 day, 2 days, 3 days.
Change in ketosis.
Time Frame: 1 day, 2 days, 3 days.
Change in circulating (beta-hydroxybutyrate) ketones in response to prolonged fasting.
1 day, 2 days, 3 days.
Change in body mass
Time Frame: 1 day, 2 days, 3 days.
Change in body mass, pre-post, and during the prolonged fast.
1 day, 2 days, 3 days.
Change in blood pressure
Time Frame: 1 day, 2 days, 3 days.
Change in blood pressure pre-, post-, and during the prolonged fast
1 day, 2 days, 3 days.
Change in interstitial fluid glucose concentrations
Time Frame: 1 day, 2 days, 3 days.
Change in interstitial fluid glucose concentrations pre-, post-, and during the prolonged fast (assessed via continual glucose monitoring)
1 day, 2 days, 3 days.
Change in amino acid metabolism
Time Frame: 3 days.
Change in amino acid metabolism (i.e. BCAAs and ketoacids) in skeletal muscle
3 days.
Change in amino acid metabolism
Time Frame: 3 days.
Change in amino acid metabolism (i.e. BCAAs and ketoacids) in adipose tissue
3 days.
Change in amino acid metabolism
Time Frame: 3 days.
Change in amino acid metabolism (i.e. BCAAs and ketoacids) in circulation
3 days.
Change in postprandial glucose responses.
Time Frame: 3 days.
Change in postprandial glucose (mmol/L) response to a standardised meal before and after 3 days of fasting.
3 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 28, 2021

Primary Completion (Estimated)

May 30, 2024

Study Completion (Estimated)

May 30, 2024

Study Registration Dates

First Submitted

September 7, 2021

First Submitted That Met QC Criteria

July 26, 2023

First Posted (Actual)

August 4, 2023

Study Record Updates

Last Update Posted (Actual)

August 4, 2023

Last Update Submitted That Met QC Criteria

July 26, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • PF

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adiposity

Clinical Trials on Prolonged Fasting

Subscribe